Gilead Sciences, Inc. PEG Ratio

Data as of June 01, 2026

How It's Calculated

What This Means

Gilead Sciences, Inc.'s PEG ratio of 2.14 is above 2, suggesting the stock may be overvalued relative to its growth rate. Investors are paying a premium for each unit of earnings growth.

About Gilead Sciences, Inc.

Gilead Sciences, Inc. (GILD) operates in the Healthcare sector, specifically in Drug Manufacturers - General. With a market capitalization of about $166.90B, it ranks as a large-cap stock — a major established company.

Shares recently traded near $134.43, within a 52-week range of $104.46 to $157.29 (-14.5% from the high, +28.7% from the low). Beta of 0.33 indicates relatively lower volatility versus the market.

Trailing profit margin is about 31.0%, signaling a strong profit margin relative to many peers.

Understanding This Metric

The PEG ratio adjusts the PE multiple for expected earnings growth, helping compare fast-growing and slow-growing names on a more equal footing. For Gilead Sciences, Inc., a PEG near 1 is often described as fairly valued relative to growth, though the growth estimate itself can change quickly with guidance revisions.

Sector Comparison

Among Healthcare names on our S&P 100 coverage, Gilead Sciences, Inc.'s PEG ratio of 2.14 can be compared with peers such as LLY (1.48), JNJ (2.93), UNH (1.32). Sector context helps interpretation, but each company's growth profile and balance sheet differ — use multiple metrics before drawing conclusions. View all Healthcare stocks.

Key Takeaways

• GILD is grouped in the Healthcare sector for peer comparisons.
• Recent beta of 0.33 suggests lower-than-market price sensitivity.
• Trailing profit margin of 31.0% provides context for how much earnings support the headline multiple.

Related Tools & Guides

Explore calculators and guides connected to this metric, or view all metrics for GILD.

Other GILD Metrics

Frequently Asked Questions